found that anti‐CTLA‐4 treatment enhanced the response of breast cancer mouse models to PRT, whereas neither anti‐PD‐1 nor anti‐PD‐L1 treatment significantly affected tumor control. The gene discussed is CTLA4; the disease is neoplasm.